Drug resistance in cancer often emerges through genetic mutations that alter the drug target, activate alternative pathways, or enhance drug efflux. Cancer cells can become resistant to targeted therapies by mutating the target protein, while resistance to cytotoxic drugs can occur through increased expression of drug efflux pumps like [P-glycoprotein](#). Understanding these mechanisms is critical for developing next-generation therapies that can overcome resistance.
